STOCK TITAN

ClearOne: First Finance owns about 58.3% after placement

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

ClearOne Inc. (CLRO) reports that First Finance Ltd. acquired 499,999 shares in the company’s private placement, issued November 17, 2026. The shares comprised 188,885 shares purchased for cash at $4.00 per share and 311,114 shares issued at a deemed price of $4.00 per share in exchange for the full settlement of $1,244,458.33 in debt.

After the issuance, First Finance directly owned 2,141,161 shares, or approximately 58.3% of the 3,675,411 shares outstanding. Andrew Hromyk may be deemed to beneficially own the same shares through his ownership and control of First Finance. First Finance said the acquisition supports ClearOne’s efforts to increase stockholders’ equity and regain compliance with Nasdaq Capital Market continued listing requirements, and to complete its merger agreement. Under that agreement, Vivani Medical is to receive 12,500,000 ClearOne shares as consideration for Cortigent’s outstanding common stock.

Filing Explained

This amendment also reports that First Finance cancelled, for no consideration, its warrant to buy up to 437,500 shares on August 4, 2026 and that after the November 17, 2026 issuance, neither reporting person held issuer derivatives or a right to acquire more shares, removing that warrant’s potential dilution for existing holders.

Shares acquired 499,999 shares Issued to First Finance on November 17, 2026
Cash subscription $755,540 For 188,885 shares at $4.00 per share
Debt settled $1,244,458.33 Full and final payment through the issuance of 311,114 shares at a deemed price of $4.00 per share
First Finance ownership 2,141,161 shares; approximately 58.3% Ownership after the November 17, 2026 private placement closing
Shares outstanding 3,675,411 shares Following the private placement closing on November 17, 2026
Merger consideration 12,500,000 shares ClearOne common shares Vivani Medical is to receive under the merger agreement
Cancelled warrant Up to 437,500 shares Warrant surrendered and cancelled for no consideration on August 4, 2026
Loan Conversion financial
"the Loan Conversion"
private placement financial
"in connection with a private placement by the Issuer"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
continued listing requirements regulatory
"regain compliance with the continued listing requirements"
Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.
restrictive legend regulatory
"bear a restrictive legend"
A restrictive legend is a notation printed on a stock certificate or encoded on an electronic security record that warns the holder the shares are subject to legal or contractual transfer limits. It identifies why the shares cannot be freely sold or transferred — for example because they are unregistered under federal securities laws, issued under a private placement, subject to lock-up agreements, or governed by contractual resale restrictions — and transfer usually requires satisfying conditions (such as registration, a compliance certificate, or a legal opinion) or formal removal of the legend by the issuer or transfer agent before the shares can be moved into a freely transferable form.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did First Finance acquire in CLRO?

First Finance acquired 499,999 shares, issued on November 17, 2026. This included 188,885 shares purchased for cash and 311,114 shares issued in the debt conversion.

What percentage of CLRO does First Finance own after the acquisition?

First Finance directly owned 2,141,161 shares, approximately 58.3% of ClearOne’s 3,675,411 shares outstanding following the November 17, 2026 closing. Andrew Hromyk may be deemed to beneficially own those same shares through his ownership and control of First Finance.

How much debt did First Finance convert into CLRO shares?

First Finance accepted 311,114 shares at a deemed price of $4.00 per share in full and final payment of $1,244,458.33 owed by ClearOne. The debt included a $1,000,000 loan, $44,458.33 in accrued interest, and a separate $200,000 loan.

What does the CLRO merger agreement provide for Vivani Medical?

Vivani Medical is to receive 12,500,000 shares of ClearOne common stock as consideration for all issued and outstanding Cortigent common shares. ClearOne’s wholly owned subsidiary is to merge into Cortigent, with Cortigent surviving as a wholly owned subsidiary of ClearOne.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





18506U203

(CUSIP Number)
Anna Chaykina
c/o Sichenzia Ross Ference Carmel LLP,, 1185 Avenue of the Americas, 26th Floor
New York, NY, 10036
212-930-9700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
11/13/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


First Finance Ltd.
Signature:/s/ Andrew Hromyk
Name/Title:Andrew Hromyk, Principal
Date:11/17/2026
Hromyk Andrew
Signature:/s/ Andrew Hromyk
Name/Title:Andrew Hromyk, Self
Date:11/17/2026

Keep reading